'cause there's a lot of money to be made here
For example, patients may log weight, glucose levels, and medication adherence through apps
Mutations in the C-terminal part of insulin-like growth factor (IGF)-binding protein-1 result in dimer formation and loss of IGF binding capacity
In observational data, patients on SSRIs lose slightly less weight on GLP-1 than non-SSRI users, but the difference is typically only 1-3 percentage points
xx Great post
00:10:48 Vickie Danaher In terms of serious safety concerns, orforglipron carries the same precautions and warnings as other GLP-1 agonists, so rare risks of thyroid tumors, pancreatitis, and gallbladder disease, for example